Immune hotspots have been studied in breast cancer, among others, in which they were found to be associated with better prognosis in estrogen-receptor-negative tumors [53], but were also associated with poorer prognosis in estrogen-receptor-positive tumors [54]. Here, ESR1 is linked to breast cancer.